News of Note—Russian trolls, AstraZeneca's FluMist and more


Here is some other vaccine news of note for the week:

> Russian trolls and social media bots used Twitter to spread false information about vaccines ahead of the 2016 U.S. presidential election, a new study found. Release

> The CDC endorsed AstraZeneca's FluMist for the upcoming flu season after recommending against its use for the two prior seasons. A committee recommended the nasal vaccine for the upcoming season in February. CIDRAP News article

> After health officials decided pregnant women shouldn't receive an experimental Ebola vaccine during an outbreak in the Democratic Republic of Congo, experts wrote an editorial in Stat calling for a reversal of the decision. Stat editorial


Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.